EC Number   |
Activating Compound |
Reference |
|---|
   5.6.1.6 | 1,10-phenanthroline |
- |
673218 |
| 5.6.1.6 | 1,3-diallyl-8-cyclohexylxanthine |
- |
210425 |
| 5.6.1.6 | 17beta-estradiol |
potentiates the isoprenaline-induced chloride current, can also potentiate the chloride current if conjugated to bovine serum albumin, has no effect in the absence of isoprenaline, potentiation is partially blocked by NO synthase inhibition |
675628 |
| 5.6.1.6 | 2-(pyridin-4-yl)-4H-benzo[h]chromen-4-one |
i.e. UCCF-029. Concentrations below 50 nM increase the open probability of the channel, favouring the channel transition to the an activated state. Levels above 50 nM determine inhibition of the channel by a reduction of the open time. UCCF-029 does not interfere with binding of ATP |
688304 |
| 5.6.1.6 | 2-pyrimidin-7,8-benzoflavone |
induces significant conformational changes of the isolated NBD1/NBD2 dimer in solution. 2-pyrimidin-7,8-benzoflavone does not modify the ATP binding constant, but reduces the ATP hydrolysis activity of the NBD1/NBD2 mixture. In absence of ATP, the NBD1/NBD2 dimer is disrupted by the compound, but in the presence of 2 mM ATP, the two NBDs keep dimerised, and a major change in the size and the shape of the structure is observed |
719248 |
| 5.6.1.6 | 3-isobutyl-1-methylxanthine |
- |
675158, 698802 |
| 5.6.1.6 | 3-isobutyl-1-methylxanthine |
activates |
210425 |
| 5.6.1.6 | 3-isobutyl-1-methylxanthine |
CFTR activation, together with forskolin |
674413 |
| 5.6.1.6 | 3-isobutyl-methylxanthine |
- |
750519 |
| 5.6.1.6 | 5-hydroxytryptamine |
activates CFTR in myocytes |
675622 |
